Clinical Research Directory

Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer Inclusion criteria: 1. Male or female patients:18-75 years old; 2. ECOG score:0-1; 3. Histopathologically confirmed TNM stage I-II NSCLC; 4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria); 5. Good compliance, family members agree to cooperate to receive survival follow-up; 6. Understand and voluntarily sign the informed consent. Exclusion criteria: 1. A history of previous or co-existing malignant tumors; 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Refusal to participate in the study. Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces Inclusion criteria: 1. Male or female patients:18-75 years old; 2. ECOG score:0-1; 3. Histopathologically confirmed TNM stage I-II NSCLC; 4. CT findings show solitary or multiple nodules with cystic airspaces. Exclusion criteria: 1. A history of previous or co-existing malignant tumors; 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Refusal to participate in the study.